You are here:

Olanzapine (Zyprexa®)

Advice

Recommended for restricted use within NHS Scotland.

RECOMMENDATION.

Olanzapine is the first atypical antipsychotic to be licensed for the treatment of acute mania and is at least as effective as comparator treatments. It was associated with fewer extrapyramidal side effects than haloperidol and was similar to placebo in the rate of Parkinson-like effects. The management of mania is complex due to the variable presentation of the condition, the wide range of treatment options and a lack of clear guidance on their optimum use.

The use of olanzapine in the treatment of acute mania should be restricted to patients under the overall supervision of clinicians experienced in managing this complex disorder.

Drug Details

Drug Name: Olanzapine (Zyprexa®)
SMC Drug ID: 44/03
Manufacturer: Eli Lilly and Company Ltd
Indication: Moderate to severe manic episodes
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Restricted
Date Advice Published: 6 June 2003

Back